Stopping PAH meds after sotatercept in low-risk patients
Part of Lungs & breathing clinical trials.
This trial is for adults with pulmonary arterial hypertension (PAH) who have been taking sotatercept for at least 6 months and have stable, low-risk disease. The study will check if it's safe to stop one of their other PAH treatments (a prostacyclin or selexipag).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a confirmed diagnosis of PAH.
- You have been taking sotatercept for at least 6 months.
- You take at least 2 other PAH medicines, including a prostacyclin by injection or selexipag pills.
- Your disease is classified as low or intermediate-low risk by standard guidelines.
- A recent heart catheterization shows your mean pulmonary artery pressure is 40 mmHg or less and your pulmonary vascular resistance is 5 Wood units or less.
- You are not pregnant and agree to use birth control if needed, and you have no other serious health conditions limiting life expectancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already taken part in a clinical trial of sotatercept for pulmonary arterial hypertension and done well enough to continue. It tests the long-term safety and effectiveness of staying on sotatercept, an investigational treatment that helps lower blood pressure in the lungs.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
This study tests a new medicine called sotatercept in Japanese children who have pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become narrow and stiff, making it harder for the heart to pump blood through them. The medicine may help improve how well their hearts and lungs work together.
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.